News

Ancient election offers lesson to modern voters

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

The Ophthalmology Times Resident Writers Award Program is a competitive writing program showcasing the best case studies in anterior segment.

According to a study presented at the American Society of Ophthalmic Trauma conference, patients are experiencing domestic injuries, delaying care, traveling for care, and have less insurance.

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

As more novel ophthalmic drugs and devices become available under the CMS “pass-through”designation, practices should be proactive in embracing these products.

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

The Department of Health and Human Services recently extended the national public health emergency declared for the COVID-19 pandemic, thereby extending payment and regulatory flexibilities. Amid the pandemic, ophthalmologists continue to adapt to practicing in the era of COVID-19.

Researchers are looking for options to reduce corneal surface flora in patients

The COVID-19 global pandemic continues to have an impact on ophthalmologists, their practices and daily life. For patients, there can be additional pressures that are concerning.

ASRS 2020 coverage: Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD,on behalf of the DRCR Retina Network.

Trabeculectomy may offer better results with more severe glaucoma

Investigators find treatment with EPO shows no effect on the development of ROP.

ASRS 2020 coverage: Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting. Faricimab is a bispecific antibody that simultaneously inhibits angiopoietin-2 and vascular endothelial growth factor A.

Technology is off to a good start, but improvements still needed

New research is looking past just regulating the IOP, using a single-cell RNA to identify 12 distinct cell types in trabecular meshwork.

ASRS 2020 coverage: An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

ASRS 2020 coverage: Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

During the COVID-19 pandemic, it is important to develop technologies to keep patients and staff safe, while treating the diseases of the eye

Diagnostic and monitoring advances in glaucoma need fine-tuning

About 10.1 million people could lose employer-based insurance coverage this year as a result of the Covid-19 pandemic, according to a report released by the Robert Wood Johnson Foundation.

Columbia University researchers have successfully isolated antibodies from severely ill, ventilated patients who recovered from COVID-19.

With an eye on innovation, money is driving research of new therapies and devices.

Canadian ophthalmologists receive updates on best practices amid coronavirus outbreak

A potential coronavirus vaccine has produced a promising immune response in a large, early-stage human trial.